Biotechnology - WSMV Channel 4

Latest News Releases

*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

Biotech News Releases via PRNewswireBiotechnology News Releases via PRNewswireMore>>
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...More >>
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...More >>
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today...More >>
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today...More >>
Whirlscape releases Minuum keyboard beta to early users
Whirlscape releases Minuum keyboard beta to early users
10,000 Indiegogo supporters first to try one-dimensional, virtual mobile keyboardMore >>
10,000 Indiegogo supporters first to try one-dimensional, virtual mobile keyboardMore >>
Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for...More >>
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for...More >>
Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy
Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy
regulated information - Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a new Pledge campaign for people with epilepsy and their loved ones. The Pledge empowers the...More >>
regulated information - Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a new Pledge campaign for people with epilepsy and their loved ones. The Pledge empowers the...More >>
RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants
RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants
RegeneCure announced today the start of a clinical study using the company's proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid for patients requiring dental implants. A common...More >>
RegeneCure announced today the start of a clinical study using the company's proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid for patients requiring dental implants. A common...More >>
The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools
The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools
The Pistoia Alliance is pleased to announce the release of the HELM biomolecular representation standard software toolkit and editor under the permissive open source MIT licence. HELM (Hierarchical Editing Language for...More >>
The Pistoia Alliance is pleased to announce the release of the HELM biomolecular representation standard software toolkit and editor under the permissive open source MIT licence. HELM (Hierarchical Editing Language for...More >>
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The...More >>
AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The...More >>
Bioinformatics Market Worth $7.5 Billion by 2017
Bioinformatics Market Worth $7.5 Billion by 2017
The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics...More >>
The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics...More >>
iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema
iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema
VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after...More >>
VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after...More >>
Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the...More >>
Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the...More >>
Mendor Announces CE Marking for its Diabetes Management Platform
Mendor Announces CE Marking for its Diabetes Management Platform
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance®. This cloud-based platform seeks to introduce significant benefits to all the key...More >>
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance®. This cloud-based platform seeks to introduce significant benefits to all the key...More >>
Techne Corporation Announces Acquisition Agreement
Techne Corporation Announces Acquisition Agreement
Techne Corporation (NASDAQ: TECH) (Techne) announced today that it has agreed to acquire 100% ownership of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics). Bionostics is a global...More >>
Techne Corporation (NASDAQ: TECH) (Techne) announced today that it has agreed to acquire 100% ownership of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics). Bionostics is a global...More >>
DNA Sequencing: Technologies, Markets and Companies - 2013 Report
DNA Sequencing: Technologies, Markets and Companies - 2013 Report
Research and Markets (http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing) has announced the addition of the report "DNA Sequencing - Technologies, Markets and Companies" to their offering. (Logo:...More >>
Research and Markets (http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing) has announced the addition of the report "DNA Sequencing - Technologies, Markets and Companies" to their offering. (Logo:...More >>
Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017
Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017
Research and Markets (http://www.researchandmarkets.com/research/4b8vj2/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles],...More >>
Research and Markets (http://www.researchandmarkets.com/research/4b8vj2/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles],...More >>
John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of...More >>
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of...More >>
Wulf Fischer-Knuppertz Appointed New CEO of BIOCRATES Life Sciences AG
Wulf Fischer-Knuppertz Appointed New CEO of BIOCRATES Life Sciences AG
On 1 June 2013, Dr Wulf Fischer-Knuppertz, took over as Chief Executive Officer (CEO) of the internationally operating biotech company BIOCRATES Life Sciences AG. He will from now on be responsible for the company's...More >>
On 1 June 2013, Dr Wulf Fischer-Knuppertz, took over as Chief Executive Officer (CEO) of the internationally operating biotech company BIOCRATES Life Sciences AG. He will from now on be responsible for the company's...More >>
North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
Research and Markets (http://www.researchandmarkets.com/research/cmbgcv/north_american) has announced the addition of the "North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET...More >>
Research and Markets (http://www.researchandmarkets.com/research/cmbgcv/north_american) has announced the addition of the "North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET...More >>
Boston Scientific Vercise™ DBS System demonstrates Improvement In Motor Function For Patients With Parkinson's Disease
Boston Scientific Vercise™ DBS System demonstrates Improvement In Motor Function For Patients With Parkinson's Disease
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the...More >>
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the...More >>
Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and...More >>
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and...More >>
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise™ DBS System In Treatment Of Parkinson's Disease
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise™ DBS System In Treatment Of Parkinson's Disease
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled...More >>
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled...More >>
BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend
BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend
BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a second quarter 2013 dividend of $0.235 per share of common stock. The dividend is equivalent to an annualized dividend of $0.94...More >>
BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a second quarter 2013 dividend of $0.235 per share of common stock. The dividend is equivalent to an annualized dividend of $0.94...More >>
KaloBios Appoints Donald R. Joseph as Chief Legal Officer
KaloBios Appoints Donald R. Joseph as Chief Legal Officer
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to KaloBios almost 20 years of biopharmaceutical industry experience and has worked...More >>
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to KaloBios almost 20 years of biopharmaceutical industry experience and has worked...More >>
Generex Announces $1,225,000 Capital Investment
Generex Announces $1,225,000 Capital Investment
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on June 17, 2013. The investors have agreed to...More >>
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on June 17, 2013. The investors have agreed to...More >>
Angel Medical Systems CEO Dr. David R. Fischell wins Ernst & Young Entrepreneur Of The Year® Award
Angel Medical Systems CEO Dr. David R. Fischell wins Ernst & Young Entrepreneur Of The Year® Award
Angel Medical Systems, Inc., a privately held medical device company developing implantable technologies for heart attack detection and patient alerting, announced today that its CEO, Dr. David R. Fischell was selected as...More >>
Angel Medical Systems, Inc., a privately held medical device company developing implantable technologies for heart attack detection and patient alerting, announced today that its CEO, Dr. David R. Fischell was selected as...More >>
Southern Research Institute Names Arthur J. Tipton, Ph.D. President and CEO
Southern Research Institute Names Arthur J. Tipton, Ph.D. President and CEO
BIRMINGHAM, Ala., June 17, 2013 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that Arthur J. Tipton, Ph.D., has been selected by its Board of Directors to serve as president and CEO of Southern...More >>
BIRMINGHAM, Ala., June 17, 2013 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that Arthur J. Tipton, Ph.D., has been selected by its Board of Directors to serve as president and CEO of Southern...More >>
Monsanto's Drought Tolerance Trait In Genuity® DroughtGard® Hybrids Receives Final Major Import Approval From China
Monsanto's Drought Tolerance Trait In Genuity® DroughtGard® Hybrids Receives Final Major Import Approval From China
China, a major importer of U.S. corn grain and dried distillers grain solubles, has officially granted full regulatory import authorization for Monsanto Company's (NYSE: MON) MON 87460 trait, the biotechnology trait in...More >>
China, a major importer of U.S. corn grain and dried distillers grain solubles, has officially granted full regulatory import authorization for Monsanto Company's (NYSE: MON) MON 87460 trait, the biotechnology trait in...More >>
Mid-Atlantic Biotech Leaders Featured On BioSpace Map
Mid-Atlantic Biotech Leaders Featured On BioSpace Map
Today BioSpace, the leading life sciences employment and news website, launched the 2013-2014 BioCapital Hotbed map campaign spotlighting the life sciences community in Virginia, Maryland, Delaware and Washington D.C.More >>
Today BioSpace, the leading life sciences employment and news website, launched the 2013-2014 BioCapital Hotbed map campaign spotlighting the life sciences community in Virginia, Maryland, Delaware and Washington D.C.More >>
Evaluate Launches Enhanced Orphan Drug Intelligence
Evaluate Launches Enhanced Orphan Drug Intelligence
The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate. To better...More >>
The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate. To better...More >>
Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase
Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase
Cedars-Sinai Medical Center, ranked one of the best healthcare organizations in the country, recovered more than $300 million by reducing net accounts receivable days with the help of OnBase, Hyland Software's enterprise...More >>
Cedars-Sinai Medical Center, ranked one of the best healthcare organizations in the country, recovered more than $300 million by reducing net accounts receivable days with the help of OnBase, Hyland Software's enterprise...More >>
University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work
University Researchers Use Biozoom Scanner To Investigate Relationship Between Stress And Work
The Biozoom (OTC QB: BIZM) scanner is the world's first portable, hand held device for the non-invasive transdermal analysis of antioxidants and other biomarkers in the human body. It replaces expensive, time consuming...More >>
The Biozoom (OTC QB: BIZM) scanner is the world's first portable, hand held device for the non-invasive transdermal analysis of antioxidants and other biomarkers in the human body. It replaces expensive, time consuming...More >>
Pancreatic Cancer Advocates Call on Congress to Protect Medical Research Funding From Sequestration Cuts
Pancreatic Cancer Advocates Call on Congress to Protect Medical Research Funding From Sequestration Cuts
Over 550 people from across the country, including nearly 100 pancreatic cancer survivors, will participate in the Seventh Annual Pancreatic Cancer Advocacy Day on June 18, 2013 to thank Congress for passing the Recalcitrant...More >>
Over 550 people from across the country, including nearly 100 pancreatic cancer survivors, will participate in the Seventh Annual Pancreatic Cancer Advocacy Day on June 18, 2013 to thank Congress for passing the Recalcitrant...More >>
ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21
ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21
The ALS Therapy Development Institute (ALS TDI) will hold its 11th annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with...More >>
The ALS Therapy Development Institute (ALS TDI) will hold its 11th annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with...More >>
Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago
Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago
Z Trim Holdings, Inc. (OTC Markets: ZTHO – News), a biotechnology company providing value-added ingredients to a variety of industries, today announced that it will be presenting a new meat application at this year's...More >>
Z Trim Holdings, Inc. (OTC Markets: ZTHO – News), a biotechnology company providing value-added ingredients to a variety of industries, today announced that it will be presenting a new meat application at this year's...More >>
BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects
BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects
During its meeting on June 5, 2013, the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation, approved $10.95 million in funding for fourteen new projects between Israeli and...More >>
During its meeting on June 5, 2013, the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation, approved $10.95 million in funding for fourteen new projects between Israeli and...More >>
AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic...More >>
AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic...More >>
A Big "LIKE" for Oral Hygiene
A Big "LIKE" for Oral Hygiene
Breezy, a portfolio company of The Trendlines Group, launched their first product this week using a platform technology enabling innovative treatment of mouth-cavity conditions. LIKE, a confectionary-based product which...More >>
Breezy, a portfolio company of The Trendlines Group, launched their first product this week using a platform technology enabling innovative treatment of mouth-cavity conditions. LIKE, a confectionary-based product which...More >>
Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At The 2013 European Hematology Association Congress
Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At The 2013 European Hematology Association Congress
Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in...More >>
Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in...More >>
Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer
Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer
Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC)...More >>
Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC)...More >>
Life Technologies Expands Range of Stem Cell Reprogramming Solutions
Life Technologies Expands Range of Stem Cell Reprogramming Solutions
Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of Epi5™ Episomal iPSC Reprogramming Vectors, the world's first product to be fully commercialized based on technology that won its developers a...More >>
Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of Epi5™ Episomal iPSC Reprogramming Vectors, the world's first product to be fully commercialized based on technology that won its developers a...More >>
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of...More >>
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of...More >>
Minimally Invasive Devices Adds $2.5 Million to its Series B
Minimally Invasive Devices Adds $2.5 Million to its Series B
Minimally Invasive Devices, Inc. (MID) today announced it has raised an additional $2.5 million from Radius Ventures, topping off its Series B financing at $11.5 million. The Series B originally raised $9 million in a...More >>
Minimally Invasive Devices, Inc. (MID) today announced it has raised an additional $2.5 million from Radius Ventures, topping off its Series B financing at $11.5 million. The Series B originally raised $9 million in a...More >>
North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017
North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017
Research and Markets (http://www.researchandmarkets.com/research/9rwvs2/north_america) has announced the addition of the "North America Injectable Drug Delivery Market - by Formulations [Liposomes, Microspheres, &...More >>
Research and Markets (http://www.researchandmarkets.com/research/9rwvs2/north_america) has announced the addition of the "North America Injectable Drug Delivery Market - by Formulations [Liposomes, Microspheres, &...More >>
Medicago Granted Patent for Influenza Virus-Like Particles in Plants
Medicago Granted Patent for Influenza Virus-Like Particles in Plants
QUEBEC CITY, June 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies...More >>
QUEBEC CITY, June 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies...More >>
Clinical Grade RetroNectin® Reagent Available To Support Gene Therapy Clinical Research
Clinical Grade RetroNectin® Reagent Available To Support Gene Therapy Clinical Research
In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin® reagent for...More >>
In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin® reagent for...More >>
Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013
Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013
Yongye International, Inc. (NASDAQ: YONG) ("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), announced today that its...More >>
Yongye International, Inc. (NASDAQ: YONG) ("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), announced today that its...More >>
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...More >>
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...More >>
PAREXEL Invites Public To Listen To Live Webcast Of Its Investor Day June 26, 2013
PAREXEL Invites Public To Listen To Live Webcast Of Its Investor Day June 26, 2013
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Wednesday, June 26, 2013, from 8:30 a.m. to...More >>
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Wednesday, June 26, 2013, from 8:30 a.m. to...More >>
NGM Biopharmaceuticals and MedImmune, AstraZeneca's Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
NGM Biopharmaceuticals and MedImmune, AstraZeneca's Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel...More >>
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel...More >>
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy...More >>
Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy...More >>
Elcelyx Therapeutics to Present Clinical Data on NewMet™ in Type 2 Diabetes at the 2013 American Diabetes Association Scientific Sessions
Elcelyx Therapeutics to Present Clinical Data on NewMet™ in Type 2 Diabetes at the 2013 American Diabetes Association Scientific Sessions
Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet™, a delayed-release formulation of generic metformin, at the 73rd Scientific...More >>
Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet™, a delayed-release formulation of generic metformin, at the 73rd Scientific...More >>
Lineage Therapeutics Markets Authorized Generic Epinephrine Auto-Injector
Lineage Therapeutics Markets Authorized Generic Epinephrine Auto-Injector
Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick® by Amedra Pharmaceuticals LLC, for the emergency treatment of...More >>
Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick® by Amedra Pharmaceuticals LLC, for the emergency treatment of...More >>
Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty Pharma believes it to be a clear frustrating tactic that offers shareholders no...More >>
Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty Pharma believes it to be a clear frustrating tactic that offers shareholders no...More >>
Biozoom Exercises Purchase Option Under Joint Venture Agreement With Spectroscopic Technology Developer, Opsolution
Biozoom Exercises Purchase Option Under Joint Venture Agreement With Spectroscopic Technology Developer, Opsolution
Biozoom (OTC QB: BIZM) exercised its option, under a joint venture agreement, to acquire 19.9% of Opsolution, a research and development company dedicated to advancing spectroscopic technology. Pursuant to the joint venture...More >>
Biozoom (OTC QB: BIZM) exercised its option, under a joint venture agreement, to acquire 19.9% of Opsolution, a research and development company dedicated to advancing spectroscopic technology. Pursuant to the joint venture...More >>
Stem Cells May Help Some With Avascular Necrosis (AVN)
Stem Cells May Help Some With Avascular Necrosis (AVN)
Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy...More >>
Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy...More >>
InterMune Announces Publication of Pricing and Reimbursement Conditions for Esbriet® (pirfenidone) in Italy
InterMune Announces Publication of Pricing and Reimbursement Conditions for Esbriet® (pirfenidone) in Italy
InterMune, Inc. (NASDAQ: ITMN) today announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet® (pirfenidone), and that the agreement has been published in...More >>
InterMune, Inc. (NASDAQ: ITMN) today announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet® (pirfenidone), and that the agreement has been published in...More >>
Mast Therapeutics Prices Public Offering Of Units
Mast Therapeutics Prices Public Offering Of Units
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the pricing of an underwritten public offering of 50,000,000 units, each unit consisting of a fixed combination of one share of common stock and one warrant to...More >>
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the pricing of an underwritten public offering of 50,000,000 units, each unit consisting of a fixed combination of one share of common stock and one warrant to...More >>
Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that it has closed the third and final tranche of its Series J Private Placement of Convertible Preferred Stock and Warrants (the "Series J...More >>
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that it has closed the third and final tranche of its Series J Private Placement of Convertible Preferred Stock and Warrants (the "Series J...More >>
Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
The Pittsburgh Life Sciences Greenhouse (PLSG) today announced a reduction in staff and levels of investment that were necessitated by delays in portfolio company exits caused primarily by the current overall investment...More >>
The Pittsburgh Life Sciences Greenhouse (PLSG) today announced a reduction in staff and levels of investment that were necessitated by delays in portfolio company exits caused primarily by the current overall investment...More >>
Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease
Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease
Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the...More >>
Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the...More >>
Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of...More >>
Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of...More >>
PAREXEL International Appoints Ingo Bank As Senior Vice President And Chief Financial Officer
PAREXEL International Appoints Ingo Bank As Senior Vice President And Chief Financial Officer
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ingo Bank has been appointed Senior Vice President and will become Chief Financial Officer on...More >>
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ingo Bank has been appointed Senior Vice President and will become Chief Financial Officer on...More >>
Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)
Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today described the steps...More >>
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today described the steps...More >>
Cempra Announces Proposed Public Offering of Common Stock
Cempra Announces Proposed Public Offering of Common Stock
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced its intention to...More >>
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced its intention to...More >>
FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of...More >>
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of...More >>
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call for an independent review of the safety data of incretin-based therapies. At BIPI...More >>
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call for an independent review of the safety data of incretin-based therapies. At BIPI...More >>
Bluestar Silicones Presents Elastomer Solutions At Medical Design And Manufacturing (MD&M) East Show
Bluestar Silicones Presents Elastomer Solutions At Medical Design And Manufacturing (MD&M) East Show
Bluestar Silicones will showcase its new Silbione® silicone elastomer solutions, including low durometer liquid silicone rubber (LSR) and self-bleeding LSR, at the upcoming Medical Design & Manufacturing (MD&M) East...More >>
Bluestar Silicones will showcase its new Silbione® silicone elastomer solutions, including low durometer liquid silicone rubber (LSR) and self-bleeding LSR, at the upcoming Medical Design & Manufacturing (MD&M) East...More >>
Supreme Court Ruling Today Allows DNATraits to Offer Low Cost BRCA Breast and Ovarian Cancer Gene Testing in U.S.
Supreme Court Ruling Today Allows DNATraits to Offer Low Cost BRCA Breast and Ovarian Cancer Gene Testing in U.S.
Thanks to today's U.S. Supreme Court decision opening the door to greater access to genetic medicine by American patients and their health care providers, testing for genes specifically linked to breast, ovarian and...More >>
Thanks to today's U.S. Supreme Court decision opening the door to greater access to genetic medicine by American patients and their health care providers, testing for genes specifically linked to breast, ovarian and...More >>
IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented...More >>
IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented...More >>
RRD International Names J. Scott Tarrant President
RRD International Names J. Scott Tarrant President
RRD International, a product development company that provides expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors, announced today the appointment of J. Scott Tarrant as...More >>
RRD International, a product development company that provides expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors, announced today the appointment of J. Scott Tarrant as...More >>
Pharmax™ Topical Creams Use Exclusive Patented Trans-dermal Delivra™ Technology from Delivra Inc.
Pharmax™ Topical Creams Use Exclusive Patented Trans-dermal Delivra™ Technology from Delivra Inc.
Multi-million dollar investment allows for continued clinical studies on the Delivra™ TechnologyMore >>
Multi-million dollar investment allows for continued clinical studies on the Delivra™ TechnologyMore >>
Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) today announced that it has established a record date and a meeting date for the special meeting of its stockholders to consider and vote upon a proposal to adopt the previously...More >>
Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) today announced that it has established a record date and a meeting date for the special meeting of its stockholders to consider and vote upon a proposal to adopt the previously...More >>
Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018
Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018
Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen,...More >>
Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen,...More >>
From Autism to Diabetes to Parkinson's Disease: Pew Funds 22 Early-Career Scientists to Take Calculated Risks
From Autism to Diabetes to Parkinson's Disease: Pew Funds 22 Early-Career Scientists to Take Calculated Risks
Twenty-two of the nation's most enterprising researchers were named Pew Scholars in the Biomedical Sciences by The Pew Charitable Trusts today. The scholarships provide flexible funding to early-career scientists...More >>
Twenty-two of the nation's most enterprising researchers were named Pew Scholars in the Biomedical Sciences by The Pew Charitable Trusts today. The scholarships provide flexible funding to early-career scientists...More >>
Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled...More >>
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled...More >>
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected...More >>
NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected...More >>
NW Bio Has Initiated Its DCVax®-Direct Phase I/II Trial For All Solid Tumor Cancers
NW Bio Has Initiated Its DCVax®-Direct Phase I/II Trial For All Solid Tumor Cancers
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that its 60-patient Phase I/II clinical trial of...More >>
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that its 60-patient Phase I/II clinical trial of...More >>
STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis
STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis
Results from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 3 study published today in The Lancet showed patients with active psoriatic arthritis who received either STELARA® (ustekinumab) 45 mg or 90 mg...More >>
Results from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 3 study published today in The Lancet showed patients with active psoriatic arthritis who received either STELARA® (ustekinumab) 45 mg or 90 mg...More >>
Life Technologies Acquires LSK, Leading Instruments Distributor in Korea
Life Technologies Acquires LSK, Leading Instruments Distributor in Korea
Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Life Science Korea (LSK), a leading instrument distributor based in Seoul, South Korea. LSK has been Life Technologies' primary instrument...More >>
Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Life Science Korea (LSK), a leading instrument distributor based in Seoul, South Korea. LSK has been Life Technologies' primary instrument...More >>
Frost & Sullivan: mHealth Serves as the Catalyst for Healthcare's Evolution
Frost & Sullivan: mHealth Serves as the Catalyst for Healthcare's Evolution
The market for mobile health (mHealth) products and services is an important area, serving as a catalyst for healthcare's evolution to dramatically alter care delivery and the patient experience. In the health system of...More >>
The market for mobile health (mHealth) products and services is an important area, serving as a catalyst for healthcare's evolution to dramatically alter care delivery and the patient experience. In the health system of...More >>
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its...More >>
PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its...More >>
Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China...More >>
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China...More >>
Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding...More >>
Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding...More >>
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with...More >>
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with...More >>
AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis
AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis
AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the...More >>
AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the...More >>
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4...More >>
PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4...More >>
Alzheimer's Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
Alzheimer's Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated...More >>
The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated...More >>
Anthera Pharmaceuticals Announces Personnel Changes
Anthera Pharmaceuticals Announces Personnel Changes
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice President, Finance and Administration. In this position, Ms. Liu will oversee the finance, investor relations and...More >>
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice President, Finance and Administration. In this position, Ms. Liu will oversee the finance, investor relations and...More >>
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the...More >>
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the...More >>
Celsion Corporation Issues Statement Regarding Misleading Blog Entry
Celsion Corporation Issues Statement Regarding Misleading Blog Entry
Celsion Corporation (NASDAQ: CLSN) today issued the following statement regarding a blog entry posted by Alpha Exposure, Contributor, on Seeking Alpha.com:More >>
Celsion Corporation (NASDAQ: CLSN) today issued the following statement regarding a blog entry posted by Alpha Exposure, Contributor, on Seeking Alpha.com:More >>
Non-Toxic, Non-Surgical Medical Cancer Therapies Finally Available in the U.S.
Non-Toxic, Non-Surgical Medical Cancer Therapies Finally Available in the U.S.
For the first time in the United States, the State of Indiana has approved the opening of a facility that offers Photodynamic Therapy (PDT) and Sonodynamic Therapy (SDT). These therapies use a whole new approach from the...More >>
For the first time in the United States, the State of Indiana has approved the opening of a facility that offers Photodynamic Therapy (PDT) and Sonodynamic Therapy (SDT). These therapies use a whole new approach from the...More >>
Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
Ten years ago the Program for Evolutionary Dynamics was founded at Harvard with a $30 million dollar grant from a financier called Jeffrey Epstein. Since then, the Program, under the direction of Martin Nowak, a professor of...More >>
Ten years ago the Program for Evolutionary Dynamics was founded at Harvard with a $30 million dollar grant from a financier called Jeffrey Epstein. Since then, the Program, under the direction of Martin Nowak, a professor of...More >>
Scotland Continues to Forge Ahead in Stem Cell Research
Scotland Continues to Forge Ahead in Stem Cell Research
Scotland's standing as Europe's largest and most highly regarded stem cell research community has been reaffirmed recently by announcements of funding from the UK Medical Research Council (MRC) and the British Heart...More >>
Scotland's standing as Europe's largest and most highly regarded stem cell research community has been reaffirmed recently by announcements of funding from the UK Medical Research Council (MRC) and the British Heart...More >>
Catalent Pharma Solutions Breaks Ground On A Major Expansion Of Its Winchester, Kentucky Controlled Release Manufacturing Facility
Catalent Pharma Solutions Breaks Ground On A Major Expansion Of Its Winchester, Kentucky Controlled Release Manufacturing Facility
Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, has announced a major expansion of its controlled release drug manufacturing facility in Winchester, Kentucky. The...More >>
Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, has announced a major expansion of its controlled release drug manufacturing facility in Winchester, Kentucky. The...More >>
Biozoom Launches Sales & Business Development Office In Strategic Southern California Location
Biozoom Launches Sales & Business Development Office In Strategic Southern California Location
Biozoom (OTC QB: BIZM), creator of the world's first handheld, non-invasive spectroscopic device for measuring health and wellness biofeedback, announced the opening of a strategic sales and business development office...More >>
Biozoom (OTC QB: BIZM), creator of the world's first handheld, non-invasive spectroscopic device for measuring health and wellness biofeedback, announced the opening of a strategic sales and business development office...More >>
Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
Today, Zacks Investment Ideas feature highlights Features: Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), Regeneron (Nasdaq:REGN-Free Report), Celgene...More >>
Today, Zacks Investment Ideas feature highlights Features: Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), Regeneron (Nasdaq:REGN-Free Report), Celgene...More >>
David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
Johnson & Johnson today named David Julius, PhD, chair of the Department of Physiology at the University of California, San Francisco (UCSF), the winner of the 2013 Dr. Paul Janssen Award for Biomedical Research. Dr....More >>
Johnson & Johnson today named David Julius, PhD, chair of the Department of Physiology at the University of California, San Francisco (UCSF), the winner of the 2013 Dr. Paul Janssen Award for Biomedical Research. Dr....More >>
Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the...More >>
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the...More >>
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival...More >>
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival...More >>
A Finnish Company Enters International Markets With World Class Genetics Technology
A Finnish Company Enters International Markets With World Class Genetics Technology
Blueprint Genetics has launched a new genetic testing technology for professional use in hospitals. The gene sequencing technology is based on Stanford University research and can effectively analyse rare hereditary human...More >>
Blueprint Genetics has launched a new genetic testing technology for professional use in hospitals. The gene sequencing technology is based on Stanford University research and can effectively analyse rare hereditary human...More >>

Healthy 4 LifeMore>>
Healthy 4 Life for Headline Box
Theatre helping autistic children improve communication
Theatre helping autistic children improve communication
Updated: Friday, June 14 2013 3:14 PM EDT2013-06-14 19:14:16 GMT
A unique camp in Middle Tennessee camp is helping children with autism learn important life skills. Communication is a big struggle for kids with autism, but this summer they're getting the opportunityMore >>
A unique camp in Middle Tennessee camp is helping children with autism learn important life skills.More >>
TV commercials may spur junk food habit in kids
TV commercials may spur junk food habit in kids
The types of TV shows that families watch influences the amount of junk food that preschool children eat, a new study suggests.More >>
The types of TV shows that families watch influences the amount of junk food that preschool children eat, a new study suggests.More >>
Antiviral drugs help prevent HIV infection in IV drug users
Antiviral drugs help prevent HIV infection in IV drug users
By Saundra Young, CNN updated 6:03 PM EDT, Wed Jun 12, 2013 (CNN) -- Treating intravenous drug users with antiviral drugs many reduce their chances of HIV infection, according to a new study publishedMore >>
Treating intravenous drug users with antiviral drugs many reduce their chances of HIV infection, according to a new study published Wednesday in the British medical journal The Lancet.
More >>
Teens learn health benefits of CrossFit
Teens learn health benefits of CrossFit
Updated: Wednesday, June 12 2013 2:07 PM EDT2013-06-12 18:07:20 GMT
http://www.stevesclubnashville.org/index.htmlCopyright 2013 WSMV (Meredith Corporation). All rights reserved.More >>
Some Middle Tennessee teens are busy this summer learning about the CrossFit workout program.More >>
Feds: Morning-after pill appeal officially on hold
Feds: Morning-after pill appeal officially on hold
After setting off a storm of criticism from abortion rights groups, upset that a Democratic president had sided with social conservatives, the Obama administration says it will comply with a judge's order to...More >>
The Obama administration's appeal in the legal fight over morning-after pills has been officially put on hold until a judge weighs a new plan to allow girls of all ages to buy the contraceptives without a prescription,...More >>
Is food at the farmers market healthier?
Is food at the farmers market healthier?
Updated: Tuesday, June 11 2013 6:29 PM EDT2013-06-11 22:29:44 GMT
Farmers markets continue to grow in popularity as the public seeks to eat local, but is that food worth the extra cost?
More >>
Farmers markets continue to grow in popularity as the public seeks to eat local, but is that food worth the extra cost?
More >>

News Releases via PR NewswireNews Releases via PR NewswireMore>>
Entertainment News Releases via PRNewswire
Entertainment
Entertainment News Releases via PRNewswire
Travel
Travel News Releases via PRNewswire
Political Campaigns
Political Campaigns News Releases via PRNewswire
Medicine & Pharmaceuticals
Medicine & Pharmaceuticals News Releases via PRNewswire
Film & Motion Picture News Releases via PRNewswire
Film & Motion Picture
Film & Motion Picture News Releases via PRNewswire
Economic News and Analysis
Economic News Releases via PRNewswire
Computer Software
Computer Software News Releases via PRNewswire
Computer Networks
Computer Networks News Releases via PRNewswire
Computer Hardware
Computer Hardware News Releases via PRNewswire
Biotech News Releases via PRNewswire
Biotechnology
Biotechnology News Releases via PRNewswire

Biotechnology - WSMV Channel 4

Biotech News Releases via PRNewswireBiotechnology News Releases via PRNewswireMore>>